Form 8-K - Current report:
SEC Accession No. 0001493152-24-003318
Filing Date
2024-01-22
Accepted
2024-01-22 17:12:05
Documents
16
Period of Report
2024-01-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43646
2 ex10-1.htm EX-10.1 89046
3 ex10-1_001.jpg GRAPHIC 9296
4 ex10-1_002.jpg GRAPHIC 11498
5 ex10-1_003.jpg GRAPHIC 3016
  Complete submission text file 0001493152-24-003318.txt   355355

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE impb-20240118.xsd EX-101.SCH 3036
7 XBRL LABEL FILE impb-20240118_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE impb-20240118_pre.xml EX-101.PRE 22373
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3159
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 333-253037 | Film No.: 24549777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)